BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The long, strange trip to turn psychedelic drugs into approved medicines has hit a bad batch of developments in recent months ...

ST. LOUIS, Mo. and WOODBURY, Minn., Nov. 12, 2024 /PRNewswire/ -- Kindeva Drug Delivery, a global CDMO and drug delivery ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

We signed three new platform license agreements during the quarter that ... During the quarter Genmab's GEN1057, an ...

CAMBRIDGE, United Kingdom, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast ... research collaboration with MSD (tradename of ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Collaborations: Mersana continues to advance its Johnson & Johnson and Merck KGaA ... on the development of novel ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

"We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “For many with HCM, the path to diagnosis and ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...